NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 2 - Cardiovascular system 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing
Links:
Hypertension Resources For Health Professionals NICE guideline NG136 Hypertension in adults: diagnosis and management
02.12 Lipid-regulating drugs

Alirocumab 75mg/mL, 150mg/mL (Praluent®)
(Pre-filled pen or syringe)

RED
Restricted Drug Restricted
FOR ALL PRESCRIBING - a completed and approved HIGH COST DRUG compliance form is required. Complete on Blueteq (link on front page).

Prescribing initiation and continuation by Consultant Chemical Pathologist only.

For treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) and mixed dyslipidaemia in accordance with NICE TA393 (alirocumab).
BNF BNFc SPC
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

Bempedoic acid (Nilemdo®)
(180 mg film-coated tablets)

GREEN
Formulary

For patients who are contraindicated or intolerant of statins and have not reached lipid targets

-40% non-HDL reduction for primary prevention

-40% non-HDL reduction or HDL < 2.5mmol/L and/or LDL-C < 1.8mmol/L for secondary prevention

 

Also for use in accordance with the following NICE TA and local guidance document: 

 

Entry reviewed: March 2025

BNF BNFc SPC
Bempedoic acid and Bempedoic acid with Ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia NICE TA 694 Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia

Bempedoic acid / ezetimibe (Nustendi ®)
(180 mg/10 mg film-coated tablets)

GREEN
Formulary

For patients who are contraindicated or intolerant of statins and have not reached lipid targets

-40% non-HDL reduction for primary prevention

-40% non-HDL reduction or HDL < 2.5mmol/L and/or LDL-C < 1.8mmol/L for secondary prevention

 

Also for use in accordance with the following NICE TA(s) and local guidance:

 

Entry reviewed: March 2025

BNF BNFc SPC
Bempedoic acid and Bempedoic acid with Ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia NICE TA 694 Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia

Evolocumab 140mg/mL (Repatha® )
(Pre-filled pen or syringe)

RED
Restricted Drug Restricted
FOR ALL PRESCRIBING - a completed and approved HIGH COST DRUG compliance form is required. Complete on Blueteq (link on front page).

Prescribing initiation and continuation by Consultant Chemical Pathologist only.

For treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) and mixed dyslipidaemia in accordance with NICE TA394 (evolocumab).
BNF BNFc SPC
NICE TA 394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

Inclisiran (Leqvio®)
(284mg/1.5ml solution for injection pre-filled syringes)

GREEN
Formulary

To be used in accordance with the following NICE TA and local guidance.

 

Entry update March 2025

BNF BNFc SPC
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia BLMK NICE TA 733 Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
02.12 Bile acid sequestrants
02.12 Ezetimibe
02.12 Fibrates
02.12 Statins
02.12 Nicotinic acid group
02.12 Omega-3 fatty acid compounds
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.